CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 367 enrolled
Drug / intervention
suPARnostic® TurbiLatex Assay on Roche cobas c501other
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07466524
NCT07466524N/ACompleted
CompareCT.gov

suPAR ≥6 ng/mL for Predicting Severe Respiratory Failure in U.S. Adults Hospitalized With COVID 19 (suPAR US The Michigan Cohort Heterogeneity Study)

ViroGates A/S·observational·Posted Mar 12, 2026·Updated Mar 20, 2026

In Brief

An observational study evaluating suPARnostic® TurbiLatex Assay on Roche cobas c501 for COVID-19 and 2 related conditions. Completed, enrolled 367 participants across 1 site.

Detailed Summary

This is a retrospective, non interventional cohort study using stored plasma samples from appoximately 300 adults hospitalized with confirmed COVID 19. Baseline suPAR measured using the suPARnostic TurbiLatex assay on the Roche cobas c501.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19, Severe Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome
CountriesUnited States
CollaboratorsUniversity of Michigan, The University of Texas Medical Branch, Galveston

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedMar 12, 2026
Enrollment StartFeb 1, 2020
Primary CompletionOct 19, 2022
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 4 months ago

Interventions

suPARnostic® TurbiLatex Assay on Roche cobas c501other

Quantitative measurement of soluble urokinase plasminogen activator receptor (suPAR) in human EDTA plasma using the suPARnostic TurbiLatex particle enhanced turbidimetric immunoassay performed on the Roche Diagnostics cobas c501 analyzer. Results are reported in ng/mL and interpreted using a pre specified clinical threshold of 6 ng/mL to identify patients at increased risk for progression to severe respiratory failure.